Skip to content

Impact of Guided Biofilm Therapy on Epithelial and Mesenchymal Biomarkers in Periodontitis Patients

Impact of Guided Biofilm Therapy on Gingival Crevicular Fluid Epithelial and Mesenchymal Biomarkers in Periodontitis Patients: A Randomized Controlled Clinical Trial

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT07286916
Enrollment
18
Registered
2025-12-16
Start date
2026-01-04
Completion date
2026-06-01
Last updated
2026-02-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Periodontitis

Keywords

Guided biofilm therapy, Gingival crevicular fluid, Epithelial Mesenchymal Transition, Periodontitis

Brief summary

The goal of this clinical trial is to investigate the clinical and biochemical effects of the guided biofilm therapy protocol as an alternative to the conventional non-surgical periodontal therapy in patients with periodontitis. The main question it aims to answer is: Does the guided biofilm therapy (GBT) protocol have an impact on gingival crevicular fluid (GCF) epithelial and mesenchymal biomarkers in patients with periodontitis? All patients will be instructed to brush their teeth twice daily and will be supplied with the same type of toothpaste and toothbrush, with suitable interdental aids. All patients will be instructed to attend again after 7 days. At baseline, full-mouth periodontal charting and radiographs will be obtained and after 1-hour, GCF samples will be collected from both test and control groups. Sites allocated to control group will undergo supragingival debridement by using ultrasonic device. After one week, the control group will receive RSD using area specific (Gracey) curettes (Medesy, Italy) according to the 24-hours protocol and will receive teeth polishing by using rubber polishing cups and tooth polishing paste, while the test group will receive a full GBT protocol which includes eight steps: (1) ASSESS, (2) DISCLOSE, (3) MOTIVATE, (4) AIRFLOW, (5) PERIOFLOW, (6) PIEZON PS\*, (7) CHECK, and (8) RECALL. After finishing the treatment session, the patients will be asked to attend for follow up, clinical evaluation of PI, BOP, PPD, and CAL, and GCF samples collection after 1 month and 3 months.

Interventions

Control group sites that will receive conventional NSPT will undergo supragingival debridement by using ultrasonic device at baseline. After one week, sites will receive root surface debridement (RSD) using area specific (Gracey) curettes (Medesy, Italy) according to the 24-hours protocol.

Test group sites will receive guided biofilm therapy (GBT) protocol using the Airflow Prophylaxis Master device by EMS which includes EMS DISCLOSING AGENT making the biofilm visible, EMS AIRFLOW combined with PLUS erythritol powder for removing biofilm, discoloration, and early calculus, PERIOFLOW removing the biofilm in deep periodontal pockets gently and thoroughly, and finally PIEZON PS for removing the remaining calculus.

Sponsors

University of Baghdad
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Outcomes Assessor)

Intervention model description

The study is a 2 arm, split-mouth, double blinded, randomized clinical trial. The first group is control group will receive conventional NSPT (scaling & root surface debridement (RSD)), while the second group is the test group will be treated according to the GBT protocol.

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

1. Adult subjects (\>18 years). 2. Subjects are not currently under active periodontal therapy or joining other trial in the last 3 months. 3. Patients must be diagnosed with generalized unstable periodontitis with bilateral, symmetrical distribution of PPD ≥ 4mm and positive BOP. \-

Exclusion criteria

1. Patients not diagnosed with periodontitis. 2. Patients consuming antibiotics. 3. Regular users of nonsteroidal anti-inflammatory drugs (NSAIDs). 4. Patients receiving periodontal treatment 3-months prior to the study. 5. Pregnant or mothers in a breastfeeding period. 6. Third molars and teeth with furcation involvement. 7. Patients taking antioxidant supplements. 8. Patients with heavy calculus that would prevent PerioPaper strips entrance to the periodontal pocket. 9. Patient with pulmonary diseases and with a history of allergy to erythritol. 10. Patients not willing to participate. -

Design outcomes

Primary

MeasureTime frameDescription
Change in probing pocket depth (PPD)3 monthsAfter treatment completion PPD ≤4mm with no BOP at 4mm pockets

Secondary

MeasureTime frame
Clinical attachment level (CAL)3 months
Bleeding on probing (BOP)3 months
Plaque index (PI)3 months
Levels of gingival crevicular fluid (GCF) biomarkers3 months

Countries

Iraq

Contacts

CONTACTIbrahim Haider Sadeq, B.D.S
Ibrahim.Ata2405@codental.uobaghdad.edu.iq009647722247642

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 28, 2026